ContextCare of patients with heart failure has been revolutionized throughout the past
decade. A paradigm shift in the strategy for treating heart failure caused by systolic
dysfunction is in progress. Despite the initial perception about β-blockers' safety, they are
now the most extensively studied class of agents in the treatment of heart failure and have
emerged as an important intervention to improve the clinical outcomes of heart failure
patients. ObjectiveTo provide scientific rationale for the use of β-blockers for patients with …